Related Experiment Video
Updated: Mar 26, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.7K
Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities
Nicola Logallo1,2, Christopher E Kvistad3,4, Aliona Nacu3,4
1Department of Clinical Medicine, University of Bergen, Jonas Lies vei 65, 5021, Bergen, Norway. nicola.logallo@gmail.com.
CNS Drugs
|January 23, 2016
Summary
Finding better stroke treatments like tenecteplase and desmoteplase remains challenging. While showing promise, definitive clinical evidence of their superiority over alteplase for acute ischemic stroke is still needed.
Area of Science:
- Neurology
- Pharmacology
- Cardiovascular Medicine
Background:
- Alteplase is the current standard for acute ischemic stroke treatment.
- Developing superior thrombolytic alternatives remains a critical unmet need.
- Tenecteplase and desmoteplase show improved pharmacological properties over alteplase.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of novel thrombolytics.
- To assess the potential of desmoteplase as an alternative to alteplase in ischemic stroke.
- To identify optimal therapeutic strategies for acute stroke reperfusion.
Main Methods:
- Review of major phase III clinical trials for desmoteplase in ischemic stroke.
- Analysis of safety and efficacy data comparing desmoteplase with placebo.
- Examination of trial designs focusing on patient admission times.
Main Results:
- Phase III trials of desmoteplase in late-admitted patients yielded neutral efficacy results.
- Desmoteplase demonstrated a promising safety profile in studied populations.
- Current evidence does not definitively establish superiority of novel agents over alteplase.
Conclusions:
- Further research is required to establish the clinical benefit of novel thrombolytics.
- Future trials should investigate thrombolytics in the early time window for acute ischemic stroke.
- Combination therapy with thrombectomy may enhance reperfusion outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:28Acute Coronary Syndrome IV: Interprofessional Care
440
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
440
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
645
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
645